Liraglutide Market Report 2024

This Liraglutide market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The liraglutide market size has grown strongly in recent years. It will grow from $5.87 billion in 2023 to $6.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The expansion during the historic period can be attributed to the rising incidence of type 2 diabetes diagnoses, increasing obesity rates, extensive clinical trials, heightened awareness of diabetes-related complications, and advancing innovations in drug delivery systems.

The liraglutide market size is expected to see strong growth in the next few years. It will grow to $8.9 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to expanding insurance and reimbursement policies, advancements in healthcare infrastructure, rising awareness and educational efforts, an aging population, and the growing prevalence of diabetes. Key trends during this period include the adoption of artificial intelligence and machine learning, increased demand for wearable technology, integration of continuous glucose monitoring, advancements in biotechnology, and the development of digital health platforms.

The growing diabetic population is anticipated to drive the expansion of the liraglutide market in the future. Diabetes is a chronic condition where the body struggles to regulate blood sugar levels effectively, either due to insufficient insulin production or ineffective insulin use. The rise in diabetes cases is attributed to factors such as sedentary lifestyles, poor diets, and increasing obesity rates globally. Diabetes medications such as liraglutide assist by mimicking the hormone GLP-1, which boosts insulin secretion, reduces blood sugar levels, and supports weight loss, thus aiding in the management of type 2 diabetes. For example, the International Diabetes Federation (IDF), a Belgium-based non-profit, reported that in 2.02 trillion adults (ages 20-79), or 1 in 10, were living with diabetes. This number is expected to rise to 643 million by 2030 and 783 million by 2045. Moreover, over 75% of adults with diabetes live in low- and middle-income countries. Consequently, the growing diabetic population is fueling the growth of the liraglutide market.

Leading companies in the liraglutide market are creating innovative products, such as generic GLP-1, to broaden treatment options and meet the demand for more affordable alternatives. Generic GLP-1 refers to versions of GLP-1 receptor agonists produced after the original branded medications' patent protection has expired, providing cost-effective options for treating conditions such as type 2 diabetes and obesity. For example, in June 2024, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel, launched the first generic GLP-1 similar to Victoza in the U.S. market, addressing the growing need for these therapies. Liraglutide injections are prescribed to improve blood sugar management in adults and children aged 10 and older with type 2 diabetes and to reduce the risk of cardiovascular events in adults with type 2 diabetes and existing cardiovascular conditions.

In October 2023, Biocon Limited, a biopharmaceutical company based in India, entered into a partnership with Juno Pharmaceuticals to commercialize its vertically integrated, complex formulation, Liraglutide. According to the terms of the agreement, Biocon will handle the regulatory approval process for Liraglutide and will subsequently manage the manufacturing and supply of the product in the Canadian market. Juno Pharmaceuticals, a Canada-based pharmaceutical company, specializes in introducing complex and high-value generic and biosimilar products to the market.

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA.

North America was the largest region in the liraglutide market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liraglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liraglutide is a GLP-1 receptor agonist utilized for managing type 2 diabetes and obesity. It lowers blood sugar levels and encourages weight loss by imitating the incretin hormone GLP-1. Given through subcutaneous injection, it boosts insulin secretion and curbs appetite. Liraglutide is available under the brand names Victoza for diabetes and Saxenda for obesity.

The primary brands of liraglutide are Victoza and Saxenda. Victoza is a brand name for liraglutide, a medication prescribed for type 2 diabetes. It can be obtained from hospital pharmacies, retail pharmacies, drug stores, and online pharmacies, and is used for managing diabetes and weight. It is utilized by different end-users, such as hospitals, clinics, and home care settings.

The liraglutide market research report is one of a series of new reports that provides liraglutide market statistics, including liraglutide industry global market size, regional shares, competitors with a liraglutide market share, detailed liraglutide market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide industry. This liraglutide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liraglutide market consists of sales of insulin products, weight management supplements, nutritional supplements, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.